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Background: Once daily dosing of aminoglycosides is widely used but is limited by the inconvenience of the slow infusion it requires and the
associated three-times daily infusion of a beta-lactam. Twice daily tobramycin can be given as a slow IV bolus and may be more convenient. This
study compares twice with three-times daily dosing of both tobramycin and ceftazidime.
Methods: This was a randomised, open-label, parallel group trial. CF patients presenting with an infective exacerbation were randomised to either
twice or three-times daily ceftazidime and tobramycin. Markers of treatment efficacy and safety were measured in the two groups. The primary
outcome measure was improvement in FEV1.
Results: 146 patients were randomised into the study. There was no significant difference in the two groups for improvement in FEV1% predicted
(9.93% and 7.98% for twice daily and three-times daily respectively) and similar times to next exacerbation. There were no differences in the
incidence of treatment failure, nephrotoxicity and ototoxicity.
Discussion: This study confirms that twice daily dosing of both tobramycin and ceftazidime is safe and effective and may be considered more
convenient than current dosing schedules.
© 2010 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Cystic fibrosis; Pulmonary exacerbations; Antibiotic therapy1. Introduction
Cystic fibrosis is a life-limiting autosomal recessive con-
dition. An early feature of the disease is the development of
bronchiectasis, which leads to bacterial infection of the airway
[1]. Chronic infection with Pseudomonas aeruginosa becomes
increasingly common as the patient becomes older [2] and is
associated with increased morbidity and mortality [3]. Chronic
infection is interspersed with acute infective exacerbations
requiring additional antibiotic therapy. Patients requiring
intravenous antibiotics for acute P. aeruginosa infections will⁎ Corresponding author. Department of Cystic Fibrosis, Royal Brompton
Hospital, Sydney Street, London, SW3 6NP, United Kingdom. Tel.: +44 207
351 8940; fax: +44 207 351 8052.
E-mail address: Andrew.jones1@imperial.ac.uk (A.L. Jones).
1569-1993/$ - see front matter © 2010 European Cystic Fibrosis Society. Publishe
doi:10.1016/j.jcf.2010.09.003typically be treated with a combination of a beta-lactam
antibiotic and an aminoglycoside, although a recent evaluation
of such combination therapy has suggested that there is
insufficient evidence of superiority over a single agent treatment
[4].
Aminoglycosides were originally studied and approved as a
three-times daily regimen. The efficacy of aminoglycoside
antibiotics is thought to be related to the peak concentration of
the drug at the site of infection, while toxicity is related to the
trough concentration. Aminoglycosides are also thought to
exhibit a post-antibiotic effect where bacterial killing continues
to occur when the antibiotic is no longer detectable. These
features led investigators to believe that once daily dosing of
aminoglycosides might be more effective with less frequent side
effects such as nephrotoxicity and ototoxicity [5]. However, a
number of studies have failed to show a significant improvementd by Elsevier B.V. All rights reserved.
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study in a CF population, the TOPIC study, reported equal
efficacy between once and three-times daily tobramycin given
with ceftazidime, with a trend to less nephrotoxicity in children
[7]. Over the recent years once daily dosing of aminoglycosides
has been adopted in most CF centres based on its potential to
reduce toxicity and supposed convenience over three-times daily
dosing. However the dosing schedule of the TOPIC study still
requires 3 doses of a beta-lactam antibiotic per day by infusion
and an aminoglycoside infusion. This can take up to 2 h per day
in total. It is therefore debatable whether the antibiotic course as
a whole is more convenient to patients than one including
conventional three-times daily aminoglycoside dosing where,
due to the smaller doses involved, antibiotics could all be given
as slow bolus injections.
When once daily dosing of aminoglycosides was introduced
a dose of 10 mg/kg/day was recommended. This was a higher
dose than had previously been given in three-times daily dosing
(5–7 mg/kg/day). Our centre's experience was of a higher rate
of ototoxicity with the increased dose of aminoglycoside that
led us to revert to the lower daily dose [9].
This study compares three-times daily ceftazidime and
tobramycin with twice daily dosing of both antibiotics using the
same total daily doses. It aimed to compare efficacy and safety of
the two regimens while also determining patient preference.
2. Methods
2.1. Patient population
Patients were enrolled from the adult CF population attending
the Royal Brompton Hospital (RBH). All patients were over
16 years of age and had a confirmed diagnosis of CF (sweat
chloride N60 mEq/L, sweat sodium N70 mEq/L, or two known
CF genetic mutations).
Patients were enrolled for the study when they attended RBH
to begin treatment for an infective exacerbation of CF. An ex-
acerbation was defined as symptoms and signs of an exacerbation
for which the attending physician decided that intravenous
antibiotics were required. Patients were eligible for enrollment if
they were chronically infected with P. aeruginosa sensitive to
both ceftazidime and tobramycin.
Patients were excluded from the study if they were pregnant
or breast feeding; had a known allergy to the study medication;
had a history of renal dysfunction, known deafness, or a history
of tinnitus; had a serum creatinine N130 μmol/L; had received
intravenous antibiotics in the previous two weeks; or were
culture positive for Burkholderia cepacia or Stenotrophomonas
maltophilia in their sputum.
The study was approved by the Royal Brompton Hospital/
National Heart and Lung Institute Research and Ethics Commit-
tee. All patients gave informed consent to participate in the study.
2.2. Study design
This study was a randomised, open, parallel group study.
Patients admitted to RBH for respiratory exacerbations due toP. aeruginosa were randomly assigned to receive a 10 day
course of intravenous ceftazidime 2 g three-times daily plus
tobramycin (7 mg/kg/day) in three divided doses, or ceftazidime
3 g twice daily plus tobramycin (7 mg/kg/day) in two divided
doses. Randomisation was carried out using a computer gen-
erated random number table and a block randomisation pro-
cedure. All routine therapies were continued as usual throughout
the study.
Patients were required to stay in the hospital for a minimum
of 48 h at the beginning of their antibiotic course. If they were
then well enough, they were allowed to go home to administer
the rest of their antibiotic course themselves, as per routine
clinical practice.
Tobramycin was administered intravenously as a bolus
injection over 3–5 min. Ceftazidime was given either as a bolus
over 5 min or an infusion over 30 min.
All patients had trough levels of tobramycin measured before
the third dose. Patients in the three-times daily group also had
peak levels measured 30 min post-dose. Dose adjustments were
made if the trough level was N2 mg/L in both groups and if a
peak level was out of the range 6–12 mg/L in the three-times
daily group.
At the time of the study a 10 day course of antibiotics was the
routine duration of IV therapy at the study centre. Treatment
courses could be extended to 14 days at the discretion of the
attending physician. If antibiotic treatment was continued for
greater than 14 days patient follow-up was continued but this
was considered a treatment failure.
Spirometrywasmeasured on days 0 and 10 using aVitalograph
compact (Vitalograph). Measurements of forced expiratory
volume in 1 s (FEV1), forced vital capacity (FVC) and forced
expiratory flow between 25% and 75% of forced vital capacity
(FEF25–75) were recorded.
A sputum culture was obtained at entry to the study to con-
firm the presence of P. aeruginosa.
Markers of inflammation, C-reactive protein (CRP), and full
blood count (FBC), were measured on days 0 and 10. All blood
samples were analysed in the Pathology department of the
Royal Brompton Hospital.
Nephrotoxicity was monitored in all patients involved in the
study. Nephrotoxicity was defined as a 20% rise in serum
creatinine above the value obtained at the start of the antibiotic
course. Serum creatinine levels were measured on day 0 and day
10 of the study. Urinary creatinine clearance, as calculated from
a 24 h urine collection, was measured within 24 h of starting the
antibiotic course and on day 10.
Ototoxicity was monitored in a subset of 30 patients. Oto-
toxicity was defined as elevation of hearing thresholds in con-
ventional frequency ranges (250 to 8000 Hz) of 15 dB or more
in at least two frequencies tested. Audiometry was measured
using a Kamplex KLD21 Diagnostic Audiometer, PC Werth,
Audiology HSE, with an IAC Model 250 Sound Shelter. Spe-
cific questions related to the presence of vestibular toxicity such
as dizziness, lightheadedness, and tinnitus were asked on days 0
and 10.
Those patients in the twice daily group who had previously
had a standard course of three times a day antibiotics were given
Table 1
Baseline characteristics.
BD n=59 TDS n=69 p-value
Mean (SD) Mean (SD)
Male 39/59 41/69 0.44
Age (years) 28.23 (7.12) 27.8 (9.14) 0.79
FEV1 (L) 1.33 (0.59) 1.31 (0.74) 0.87
FVC (L) 2.43 (0.95) 2.41 (0.12) 0.90
FEF25–75 (L/min) 0.55 (0.37) 0.68 (0.73) 0.34
Weight (kg) 56.31 (9.74) 54.68 (10.17) 0.36
BMI 19.78 (2.53) 19.61 (3.31) 0.75
Pulse rate 93.00 (14.79) 100.96 (16.64) 0.006
Respiratory rate 19.43 (3.94) 19.19 (3.90) 0.75
Temp (°C) 37.02 (0.79) 36.87 (0.63) 0.22
SaO2 93.32 (3.67) 92.68 (4.09) 0.35
Creatinine (μmol/L) 70.33 (14.91) 67.64 (16.27) 0.34
Creatinine clearance (mL/min) 113.17 (41.32) 104.89 (37.28) 0.28
WCC (109/L) 13.30 (5.45) 12.00 (4.65) 0.15
CRP (mg/L) 50.28 (44.74) 44.81 (46.25) 0.51
Tobramycin dose (mg/kg/day) 6.75 (1.38) 6.35 (1.74) 0.16
Duration of antibiotics (days) 11.17 (1.90) 11.29 (1.70) 0.49
FEV1 — forced expiratory volume in 1 s; CRP— C-reactive protein; FVC—
forced vital capacity; BMI — body mass index; SaO2 — oxygen saturation;
WCC— total white cell count.
Table 2
Markers of treatment efficacy and toxicity.
Day 1 to day 10 change
BD TDS p-value
Mean (SD) Mean (SD)
FEV1 (L) 0.34 (0.67) 0.19 (0.70) 0.21
FEV1% pred 9.93 (10.61) 7.89 (10.66) 0.30
FVC (L) 0.57 (0.95) 0.28 (1.07) 0.12
FVC% pred 12.80 (16.32) 9.13 (14.08) 0.20
FEF25–75 0.55 (0.06) 0.68 (0.11) 0.34
BMI (kg/m2) 0.23 (0.58) 0.26 (0.44) 0.81
WCC (109/L) −4.41 (5.00) −3.09 (4.02) 0.12
CRP (mg/L) −36.76 (41.50) −31.25 (43.92) 0.49
Creatinine Clearance (mL/min) 1.45 (40.26) 2.33 (32.98) 0.91
Creatinine (μmol/L) −3.64 (10.28) −2.30 (9.82) 0.47
FEV1 — forced expiratory volume in 1 s; FVC — forced vital capacity;
FEF25–75 — forced expiratory flow 25%–75%; BMI — body mass index;
WCC— total white cell count; CRP— C-reactive protein.
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and their reasons.
The primary outcome measure for the study was change in
FEV1. Secondary outcomes were rates of treatment failure,
toxicity and time to next exacerbation.
2.3. Power calculation
For the power calculation we used information from a
previous study [6]. We took the mean percentage improvement
in FEV1 to be 14.9% (+/−16) after a course of antibiotics. We
calculated that for a power of 80% and a significance of 5%, in a
superiority study, we would require a total of 144 patients (72 in
each arm of the study) to be able to detect a difference of 7.4%.
2.4. Statistical analysis
Chi-squared or Fischer's exact test was used to compare two
groups by means of discrete variables, and Student's T-test or
Mann–Whitney test for continuous variables. Analysis was
performed with STATA software (StataCorp, College Station,
TX, USA).
3. Results
One hundred and forty six people were enrolled into the
study.
Six patients (3 in each group) were withdrawn as they grew a
ceftazidime resistant strain of P. aeruginosa in the sputum
sample obtained at the start of the study. Twelve patients failed
to attend their day 10 follow-up, 7 in the three-times daily group
and 5 in the twice daily. One hundred and twenty eight par-
ticipants completed the study as per protocol, 59 in the twice
daily and 69 in the three-times daily regimen. All results are a
per protocol analysis.
3.1. Baseline characteristics
Table 1 shows the baseline characteristics for the patients
who completed the study as per protocol. There was no dif-
ference in sex distribution, age, lung function, BMI, clinical
state, renal function, inflammatory markers or the tobramycin
dose received. The only significant difference was pulse rate
which was significantly higher in the three-times daily group.
The mean total daily dose of tobramycin in the twice daily and
three-times daily groups was 6.75 and 6.35 mg/kg/day re-
spectively. All patients cultured P. aeruginosa in their sputum
which were sensitive to ceftazidime and tobramycin. The mean
number of days of antibiotics received in each group was not
significantly different (11.17 days vs 11.29, twice vs three-
times daily, p=0.49).
3.2. Treatment outcomes
In both groups a significant improvement in indices of lung
functionwas seenwith no significant difference between groups.
Equally, BMI increased and serum markers of inflammationwere reduced with no significant difference between groups
(Table 2).
3.3. Treatment failure
Three patients in the three-times daily group and two patients
in the twice daily group had longer than 14 days of antibiotics.
This was considered a treatment failure by the protocol
definition. There was no significant difference between groups
(p=1.0).
3.4. Nephrotoxicity
Six patients met the protocol definition of nephrotoxicity
(rise in baseline creatinine of N20%), 4 patients in the twice
1.0
Three-times daily-
censoredTwice daily-censored
Three-times dailyTwice daily
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statistically significant. None of these patients had a rise in
creatinine above the laboratory reference range.
Overall there was a trend for a decrease in serum creatinine
and an increase in creatinine clearance that was not significantly
different between groups.Cu
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0.23.5. Treatment related adverse events
Eight patients reported symptoms that were attributed to
antibiotic therapy. Six patients reported symptoms of dizziness
related to the administration of antibiotics, two in the twice daily
group and four in the three-times daily group. None required
treatment for their symptoms.
1 patient reported diarrhoea (three-times daily group) and 1
patient reported nausea (twice daily group).Days
6004002000
0.0
Fig. 1. Kaplan–Meier analysis of time to next exacerbation.3.6. Ototoxicity
31 patients completed audiometry at the beginning and end
of antibiotic treatment, eleven patients in the twice daily group
and twenty in the three-times daily group. No patients had
evidence of ototoxicity (as previously defined).3.7. Patient preference
Those patients who received twice daily antibiotics and had
previously received a course of antibiotics involving three-times
daily dosing were asked to note their preference between the
two regimens. Twenty-six patients returned the questionnaire.
All patients preferred the twice daily dosing regimen citing
convenience, less time consuming and being easier to perform
at home.3.8. Time to next exacerbation
Data on time to next exacerbation was available in eighty-
nine study participants, 46 in the twice daily group and 43 in the
three-times daily group. Those patients with no available data
on time to next exacerbation were censored as drop-outs from
the study at day 0 of follow-up.
Mean time to next exacerbation for the twice daily group was
127.09 days (median 99.5 days) compared with 148.58 days
(median 109 days) for the three-times daily group. A Kaplan–
Meier analysis (Fig. 1 and Table 3) shows no significant dif-
ference between groups, p=0.89.Table 3
At risk Kaplan–Meier analysis.
Days 0 100 200 300 400 500 600
Number at risk Twice daily 46 23 7 1 0 0 0
Three-times daily 43 22 10 5 4 2 14. Discussion
This study has demonstrated that twice daily dosing of both
ceftazidime and tobramycin is a safe and effective regimen that
is also preferred by patients when compared to three-times daily
dosing.4.1. Treatment efficacy
As yet, there is no consensus on what constitutes a successful
outcome for the treatment of an infective exacerbation of CF. In
our study we monitored the change in spirometry over the
treatment period and also retrospectively examined case notes
to determine the time to next exacerbation (TTNE). These two
outcome measures are widely used to determine treatment
success in studies examining infective exacerbations of cystic
fibrosis.
The improvements in FEV1 seen in this study (9.93% and
7.98% increase in FEV1% predicted) are comparable to other
studies (e.g. 10.4% and 10% in the TOPIC trial) [7,10,11], with
no statistical difference between twice daily and three-times
daily dosing. Equally the time to next exacerbation in both
groups (127 and 148 days) was at least no worse and potentially
better when compared with other studies which have used
TTNE as an outcome measure (84.5 and 79 days in Aaron et al.)
[12].
It is thought that the bacterial killing effect of aminoglycoside
therapy is related to its peak serum concentration. Given the
lower total daily dose of tobramycin as compared with other
studies [7] (7 mg/kg/day in our study vs 10 mg/kg/day in the
TOPIC study), it could be criticised that we were under-treating
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adopted this dose because of concerns regarding excess events of
ototoxicity when higher doses of aminoglycoside were given.
The effectiveness of ceftazidime, in contrast, is thought to be
related to time of serum concentrations above the minimum
inhibitory concentration (MIC). We did not examine the phar-
macokinetics of ceftazidime given in twice daily dosing.
However it is a recognised dosing schedule for ceftazidime. It
is possible that despite the equal daily dose, twice daily dosing
may lead to increased periods of time when the serum level of
ceftazidime is below the minimum inhibitory concentration as
compared with three-times daily dosing. It has been hypothe-
sized that outcomes for infective exacerbationsmay be improved
by continuous ceftazidime infusion, thus maintaining a steady
serum concentration of the drug. However recent studies have
shown no added benefit [13–15].
The length of antibiotic course could be criticised for being
too short at 10 days. No studies as yet have defined the optimum
duration of intravenous antibiotics for a pulmonary exacerba-
tion of CF. The current guidelines developed by the UK CF
Trust suggest a minimum of 10–14 days. At the time of the
study, 10 days was the routine clinical practice at the study
centre.
The number of treatment failures, i.e. those whose antibiotic
courses were extended beyond 14 days was similar in both
groups.
Our data therefore suggests that three-times daily is no better
than twice daily dosing with similar treatment efficacy and also
our lower daily dose of aminoglycoside and twice daily dosing
of ceftazidime are effective with comparable treatment out-
comes to other dosing schedules.
4.2. Safety
We collected data on both nephrotoxicity and ototoxicity
related to the dosing of aminoglycosides. No patients were shown
to have evidence of hearing loss asmeasured by audiometry in our
study and there was no significant difference between groups of
rates of dizziness during antibiotic administration.
We have also shown no significant difference in the oc-
currence of nephrotoxicity with a mean decrease in creatinine
and increase in creatinine clearance between groups.
We therefore conclude that twice daily dosing of amino-
glycosides is as safe as a three-times daily dosing regimen with
an equivalent daily dosing of 6–7 mg/kg/day.
4.3. Convenience
From the TOPIC trial [7] it was clear that three-times daily
and once daily dosing had equivalent efficacy and safety
profiles. The once daily dosing has therefore been adopted by a
large number of centres on the basis of convenience. The twice
daily dosing regimen allows patients to have only two sessions
of intravenous antibiotics per day. The lower dose of tobramycin
given for twice daily dosing at each session allows the drug to be
given as a slow bolus injection over approximately 3–4 min
rather than the minimum of 30 min required for the infusion ofthe once daily dose of aminoglycoside. Therefore, on the twice
daily dosing schedule, patients and nursing staff are spending
considerably less time during the day administering antibiotics.
For inpatients this may not seem important but for people who
complete their intravenous antibiotic courses at home it allows
much greater freedom during the day. Equally a twice daily
dosing schedule is more convenient to those patients who elect to
continue studying or working during their antibiotic course as it
doesn't involve receiving any antibiotics during working hours.
4.4. Limitations
Clearly there are limitations to our study. A significant num-
ber of centres now give patients OD dosing of aminoglycosides.
Our study does not include these patients to make a direct
comparison. Such a comparison needs to be an area of future
research. The study was powered for a superiority trial whereas a
trial powered for equivalence may have made the data more
robust. Assuming an FEV1 difference of 5% as being clinically
equivalent, 324 patients (162 in each arm) would be required to
determine if the two treatments were equivalent (for a power of
80% and a significance of 5%).
The study was an open-label study and our primary outcome
measure of FEV1 can be effort dependent. This does introduce
the possibility of bias. However, all spirometry was performed
by staff trained in its use and taught to ensure maximum effort
by study participants. Equally our secondary outcomes of C-
reactive protein and white cell count showed similar improve-
ments which would not be subject to such bias.
A small but significant proportion of patients were lost to
follow-up and were not included in the final analysis. However
there was no difference between groups for the rate of dropout
from the study and as such is unlikely to bias the results.
Finally, the patient preference questionnaire may be biased
as study participants were being asked to recall their preference
for a treatment regimen when the alternate regimen may have
been used a significant time in the past.
Our time to next exacerbation data was collected retrospec-
tively from case notes. This meant that we were unable to
collect data on all patients and the data we collected is based on
hospital notes only. We may have missed the treatment that
patients have received from their primary healthcare provider
without informing the study centre when they attended clinic.
In conclusion our data suggests that a lower total daily dose
of 6–7 mg/kg/day of tobramycin is effective for treating
infective exacerbations of cystic fibrosis. It also suggests that
twice daily dosing is safe and no more efficacious than three-
times daily dosing. When considering patients for intravenous
antibiotics, and especially for home antibiotics, twice daily
dosing of both ceftazidime and tobramycin may be more
convenient and less time consuming than once daily tobramycin
and three-times daily ceftazidime.
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